BioSkryb will highlight its new automation-ready ResolveDNA® and ResolveOME™ single-cell core kits, and share new breast cancer research and a spotlight presentation
DURHAM, N.C. – March 28, 2024 - BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight…
New ResolveDNA® and ResolveOME™ single-cell kits generate sequencing-ready libraries in under eight hours
DURHAM, N.C. – March 13, 2024 - BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome a…
BioSkryb to introduce new products and novel applications of industry-leading portfolio that advance the single-cell multiomics field through simultaneous interrogation of DNA, RNA, and targeted proteins from each cell
DURHAM, N.C. – January 30, 2024 - BioSkryb Genomics, a company transforming singl…
Ram Laxman brings executive leadership experience from 10x Genomics, Illumina, and Pacific Biosciences to expand BioSkryb’s international footprint
DURHAM, N.C. – November 29, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of th…
BioSkryb will participate in two CoLab Sessions on single-cell whole genome sequencing and four poster presentations with new pancreatic and breast cancer data
DURHAM, N.C. – October 30, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic vie…
As a part of the National Institute of Standards and Technology (NIST) Genome Editing Consortium, BioSkryb will help enable increased confidence in gene edited research and commercial products
DURHAM, N.C. – September 13, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by e…
Strategic distribution agreement with Research Instruments expands access to BioSkryb’s best-in-class single-cell multiomics portfolio throughout Southeast Asia
DURHAM, N.C. – August 30, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic…
U.S. issued patent expands BioSkryb’s IP portfolio to four granted patents in key geographic markets worldwide
DURHAM, N.C. – August 17, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to…
The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell genomics studies with unprecedented coverage and accuracy
DURHAM, N.C. – August 3, 2023 - BioSkryb Genomics, a pioneer in comprehensive single…
LEIDEN July 18, 2023 - BIOKÉ, a leading distributor of life science technologies throughout Europe, has partnered with BioSkryb Genomics (BioSkryb), a pioneer in comprehensive single-cell multiomic research solutions, to distribute Primary Template-directed Amplification (PTA) technology acr…
